###begin article-title 0
Impaired Antibody Response Causes Persistence of Prototypic T Cell-Contained Virus
###end article-title 0
###begin p 1
###xml 258 292 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 294 298 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 314 319 <span type="species:ncbi:10090">mouse</span>
###xml 360 364 <span type="species:ncbi:10090">Mice</span>
###xml 407 411 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1033 1036 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1041 1058 <span type="species:ncbi:11103">hepatitis C virus</span>
CD8 T cells are recognized key players in control of persistent virus infections, but increasing evidence suggests that assistance from other immune mediators is also needed. Here, we investigated whether specific antibody responses contribute to control of lymphocytic choriomeningitis virus (LCMV), a prototypic mouse model of systemic persistent infection. Mice expressing transgenic B cell receptors of LCMV-unrelated specificity, and mice unable to produce soluble immunoglobulin M (IgM) exhibited protracted viremia or failed to resolve LCMV. Virus control depended on immunoglobulin class switch, but neither on complement cascades nor on Fc receptor gamma chain or Fc gamma receptor IIB. Cessation of viremia concurred with the emergence of viral envelope-specific antibodies, rather than with neutralizing serum activity, and even early nonneutralizing IgM impeded viral persistence. This important role for virus-specific antibodies may be similarly underappreciated in other primarily T cell-controlled infections such as HIV and hepatitis C virus, and we suggest this contribution of antibodies be given consideration in future strategies for vaccination and immunotherapy.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 27 44 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 46 49 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 177 180 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 463 468 <span type="species:ncbi:10090">mouse</span>
###xml 603 608 <span type="species:ncbi:10090">mouse</span>
###xml 959 962 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 966 969 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Persistent viruses such as hepatitis C virus (HCV) or HIV can defeat the body's defense system and cause devastating epidemics worldwide. Recent attempts at vaccinating against HIV have relied on the induction of specific antiviral killer T lymphocytes but have failed to confer protection on the host. Better knowledge about how a successful defense should operate is therefore essential for developing and refining new vaccines. Here, we have used a prototypic mouse model to investigate basic defense mechanisms required to eliminate persisting viruses. Experiments in several genetically engineered mouse models show that contrary to common belief, not only antiviral killer T cells, but also antibodies (produced by B cells), are needed to prevent a virus from persisting in its host. These findings suggest that induction of antibodies, along with antiviral killer T lymphocytes, should be envisaged when devising new strategies for vaccinating against HIV or HCV.
###end p 4
###begin p 5
###xml 233 236 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 241 252 <span type="species:ncbi:11103">hepatitis C</span>
Andreas Bergthaler and colleagues reveal that T cell control of systemic persistent viral infections requires support by antibodies produced by B cells, which may have important implications for future vaccination strategies against HIV and hepatitis C.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 54 82 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 84 87 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 124 127 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 129 132 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 170 176 <span type="species:ncbi:9606">people</span>
###xml 249 252 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 257 260 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Infections associated with persistent viremia include human immunodeficiency virus (HIV) and the hepatitis B and C viruses (HBV, HCV), which affect more than 500 million people worldwide. However, available options to prevent and treat particularly HIV and HCV are unsatisfactory. To refine existing strategies aimed at combating these devastating epidemics, and to help direct future efforts, a better understanding of the immune effector pathways preventing viral persistence is of particular importance.
###end p 7
###begin p 8
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b001">1</xref>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b002">2</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b001">1</xref>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b003">3</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b005">5</xref>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b006">6</xref>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b007">7</xref>
###xml 1030 1031 1030 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b008">8</xref>
###xml 1238 1239 1238 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b009">9</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b011">11</xref>
###xml 1312 1314 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b012">12</xref>
###xml 1315 1317 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b013">13</xref>
###xml 22 56 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 58 62 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 654 658 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 719 724 <span type="species:ncbi:9606">human</span>
###xml 743 746 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 751 754 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 777 780 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 875 878 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1088 1117 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 1119 1122 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 1281 1284 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1290 1293 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
For almost a century, lymphocytic choriomeningitis virus (LCMV) infection of mice has served as a primary model to study basic mechanisms of the virus-host relationship in persistent infection [1]. It has led to the discovery of several essential concepts [2], including MHC restriction of T cells, viral mutational escape from CD8 cytotoxic T cells (CTL), CTL dysfunction in persistent infection and MHC linkage of virus control. LCMV neutralizing antibody (nAb) responses typically appear late and remain relatively weak [1]. Accordingly, the key role of CTL in controlling and resolving systemic persistent infections has initially been described for LCMV [3-5] with subsequent extension of the concept to important human pathogens such as HIV and HCV. Declining viremia in HIV coincides with the appearance of antiviral CD8 T cells [6,7], and the concept of CTL-mediated HIV control was further strengthened by the association of "protective" HLA molecules with long-term nonprogression in many so-called "elite controllers" [8]. In addition, experimental depletion of CD8 T cells in simian immunodeficiency virus (SIV)-infected macaques also underlined the importance of CTLs in the control of acute, as well as long-term infection [9-11]. Analogous observations were made in HBV- and HCV-infected monkeys [12,13].
###end p 8
###begin p 9
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b014">14</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b015">15</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b015">15</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b016">16</xref>
###xml 341 344 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 434 437 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 616 621 <span type="species:ncbi:9606">human</span>
###xml 622 625 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Apart from the virtually undisputed contribution of CTLs, evidence has accumulated to suggest that other mechanisms of immune defense are also needed to contain or resolve systemic persistent virus infection. For instance, "protective" HLA alleles are also found in up to one third of individuals with poor or undetectable immune control of HIV infection [14,15], suggesting that even potent CD8 T cell responses are insufficient for HIV control. Conversely, many "elite controllers" lack any of the known "protective" alleles [15]. Moreover, the recent failure of the CD8 T cell-based Merck "STEP" vaccine trial in human HIV infection has alerted the community and has sparked renewed interest in complementary mechanisms that may aid immune defenses against persistent viral disease [16].
###end p 9
###begin p 10
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b017">17</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b021">21</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b022">22</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b022">22</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b023">23</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b024">24</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b025">25</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b027">27</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b028">28</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b029">29</xref>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 690 694 <span type="species:ncbi:10090">mice</span>
###xml 709 712 <span type="species:ncbi:9606">man</span>
Antibodies are among the obvious candidates to complement CTL-mediated control. However, their contribution to the resolution of primary virus infections in general, and persisting ones in particular, has remained controversial. Rapid mutational escape of persisting viruses from antibody neutralization represents a major obstacle to efficient antibody-mediated control [17-21]. Moreover, observations that patients with Bruton's agammaglobulinemia can control acute viral diseases [22] helped create a generally held notion that, unlike what applies for protection against reinfection, primary viral infections were predominantly controlled by cell-mediated immunity [22]. Experiments in mice, monkeys, and man had shown that passive administration of potent nAbs or transgenic expression of a virus-neutralizing B cell receptor (BCR) can prevent infection [23,24], augment virus control during infection [25-27], or prevent the establishment of persistence [28,29]. Still, these experimental observations did not challenge the above dogma since the experimental conditions chosen did not mimic the kinetics and magnitude of the host's spontaneous nAb response (delayed and weak).
###end p 10
###begin p 11
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b030">30</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b031">31</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b032">32</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b034">34</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b035">35</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b034">34</xref>
###xml 62 66 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
Similarly, it seemed unlikely that antibodies could influence LCMV control and persistence, until B cell-deficient mice were found to control the infection only transiently, or not at all. B cell-deficient mice showed vanishing CD8 T cell function and viral recrudescence [30,31], but the conclusions became doubtful when the mice were shown to have a distorted splenic microarchitecture and intrinsically defective CD4 T cell responses [32-34]. As CD4 T cells are essential to the maintenance of effective antiviral CD8 T cell responses [35], the shortcomings in viral resistance were concluded to result from defective T help, rather than from the lack of antibody [34].
###end p 11
###begin p 12
###xml 153 159 <span type="species:ncbi:9606">humans</span>
###xml 288 292 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 530 535 <span type="species:ncbi:10090">mouse</span>
Given the outlined uncertainties, combined with the importance of such fundamental knowledge in order to refine preventive and therapeutic strategies in humans, we have readdressed the role of specific antibody responses to the control and resolution of persistent infection. We used the LCMV model to establish viral infection in genetically engineered mice that support the development of B cells, but do so only with restricted diversity and predominantly LCMV-unrelated specificity. In addition, we infected B cell-sufficient mouse models, unable to mount either serum immunoglobulin M (IgM) or immunoglobulin G (IgG) responses. Our studies reveal that virus-specific antibodies, including early adaptive IgM responses, play an essential role in reducing viral loads and ultimately determine viral clearance or persistence.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
B Cell Receptor Diversity Correlates with the Magnitude of Antiviral Antibody Responses and Determines Efficacy of Virus Control
###end title 14
###begin p 15
###xml 458 460 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b036">36</xref>
###xml 574 576 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b037">37</xref>
###xml 934 941 933 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sd001">Text S1</xref>
###xml 1084 1085 1083 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1214 1223 1205 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sg001">Figure S1</xref>
###xml 1228 1235 1219 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sd001">Text S1</xref>
###xml 1278 1280 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b038">38</xref>
###xml 1408 1409 1397 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1467 1475 1456 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 1720 1728 1707 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 1993 2001 1979 1987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 2140 2148 2126 2134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 2277 2279 2262 2264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b039">39</xref>
###xml 2328 2329 2313 2314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 2614 2616 2598 2600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b040">40</xref>
###xml 2801 2810 2785 2794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sg002">Figure S2</xref>
###xml 3299 3307 3283 3291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 3313 3314 3297 3298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">1</xref>
###xml 3847 3855 3831 3839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 4460 4462 4443 4445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b041">41</xref>
###xml 4549 4551 4532 4534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b041">41</xref>
###xml 4729 4731 4712 4714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b042">42</xref>
###xml 4964 4972 4946 4954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 10 16 <span type="species:ncbi:10090">murine</span>
###xml 26 30 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 202 207 <span type="species:ncbi:10090">mouse</span>
###xml 353 358 <span type="species:ncbi:10090">mouse</span>
###xml 421 425 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 728 754 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 796 800 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 968 972 <span type="species:ncbi:10090">mice</span>
###xml 1111 1115 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1272 1276 <span type="species:ncbi:10090">mice</span>
###xml 1370 1374 <span type="species:ncbi:10090">mice</span>
###xml 1396 1400 <span type="species:ncbi:10090">mice</span>
###xml 1440 1444 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1493 1497 <span type="species:ncbi:10090">mice</span>
###xml 1541 1545 <span type="species:ncbi:10090">mice</span>
###xml 1655 1659 <span type="species:ncbi:10090">mice</span>
###xml 1794 1798 <span type="species:ncbi:10090">mice</span>
###xml 1853 1857 <span type="species:ncbi:10090">mice</span>
###xml 1880 1884 <span type="species:ncbi:10090">mice</span>
###xml 1987 1991 <span type="species:ncbi:10090">mice</span>
###xml 2134 2138 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 2165 2169 <span type="species:ncbi:10090">mice</span>
###xml 2245 2249 <span type="species:ncbi:10090">mice</span>
###xml 2281 2285 <span type="species:ncbi:10090">mice</span>
###xml 2350 2354 <span type="species:ncbi:10090">mice</span>
###xml 2512 2516 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 2608 2612 <span type="species:ncbi:10090">mice</span>
###xml 2961 2965 <span type="species:ncbi:10090">mice</span>
###xml 2985 2989 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 3001 3005 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 3087 3091 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 3231 3236 <span type="species:ncbi:10090">mouse</span>
###xml 3321 3325 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 3483 3487 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 3616 3620 <span type="species:ncbi:10090">mice</span>
###xml 3841 3845 <span type="species:ncbi:10090">mice</span>
###xml 3935 3940 <span type="species:ncbi:10090">mouse</span>
###xml 3969 3973 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 4064 4068 <span type="species:ncbi:10090">mice</span>
###xml 4116 4120 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 4304 4308 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 4747 4751 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 4807 4811 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 4861 4865 <span type="species:ncbi:10090">mice</span>
###xml 4901 4905 <span type="species:ncbi:10090">mice</span>
###xml 4926 4930 <span type="species:ncbi:10090">mice</span>
###xml 4997 5001 <span type="species:ncbi:10090">mice</span>
###xml 5155 5159 <span type="species:ncbi:10090">mice</span>
Using the murine model of LCMV infection, we aimed here at investigating the contribution of specific antibody to prevent persistent infection. To overcome the limitations intrinsic to B cell-deficient mouse models (i.e., distorted splenic microarchitecture with resulting defects in CD4 T cell responses), we first exploited two genetically engineered mouse models with a severely narrowed, predefined BCR repertoire of LCMV-unrelated specificity. T11muMT [36] carry an immunoglobulin (Ig) heavy chain transgene in an IgM heavy chain-deficient background, whereas VI10YEN [37] combine an Ig light chain transgene with a knockin at the endogenous Ig heavy chain locus. Both constructs render the respective B cells specific for vesicular stomatitis virus (VSV) that is antigenically unrelated to LCMV (for a more detailed description of these strains, including their residual ability of generating antibody repertoire diversity, see Text S1). Unlike B cell-deficient mice, these animals exhibited a normal splenic microarchitecture in immunohistochemistry, and mounted unimpaired CD4+ T cell responses against LCMV, as determined by intracellular staining of interferon gamma (IFNgamma) upon peptide stimulation (Figure S1 and Text S1). We infected B cell-deficient muMT mice [38] (targeted deletion of the IgM transmembrane domain), BCR-restricted T11muMT and VI10YEN mice, and C57BL/6 control mice with 106 plaque-forming units (PFU) of LCMV intravenously (i.v.) (Figure 1). Unlike C57BL/6 mice that resolved viremia within 12 d, T11muMT mice exhibiting the lowest degree of BCR diversity failed to contain the infection and-like B cell-deficient muMT mice-remained viremic throughout the observation period of 96 d (Figure 1A). Similar, albeit less-pronounced, effects were seen in VI10YEN mice displaying a more diverse BCR repertoire than T11muMT mice. Seven of ten VI10YEN mice tested in three independent experiments exhibited protracted viremia as compared to C57BL/6 wild-type mice (Figure 1A and unpublished data). Even more pronounced was the impact of BCR diversity on the control of the more invasive Clone 13 strain of LCMV (Figure 1B). Only C57BL/6 mice succeeded in resolving viremia, whereas BCR-restricted VI10YEN and T11muMT mice, and B cell-deficient JHT [39] mice (targeted deletion of the immunoglobulin JH locus; JHT and muMT mice were used likewise in this study) remained viremic throughout the observation period of 123 d. Thus, BCR diversity was essential for efficient resolution of LCMV infection. Further support for this notion came from experiments in "quasimonoclonal" (QM) mice [40] with a predefined nitrophenyl-specific B cell repertoire owing to knockin of a rearranged immunoglobulin heavy chain gene in combination with an immunoglobulin light chain transgene (Figure S2). Interestingly also, the requirements for BCR diversity became apparently more stringent as the infection was prone to persistence. That is, VI10YEN mice were able to clear LCMV strain WE (LCMV-WE), albeit with some delay, but they failed at resolving chronic infection with LCMV strain Clone 13. The above patterns of virus control or persistence correlated only to a limited extent with the ability of the respective mouse strains to mount a late virus-neutralizing antibody response (Figure 1C and 1D). In LCMV Clone 13 infection, the appearance of neutralizing serum activity around day 45 after infection coincided with viral clearance. In contrast, a clear rise in LCMV-WE-nAb occurred only between 50 and 74 d after infection, i.e., more than 1 mo after viral clearance from the blood. In C57BL/6 mice, this response was consistently measured although the titers varied considerably between individual animals. With further delay and barely above the detection limit of our assays, nAbs were also measured in some VI10YEN mice (Figure 1C, not statistically significant), providing only partial correlation with this mouse strain's ability to control LCMV-WE infection. In contrast, nAbs always remained below detection levels in viremic T11muMT mice. The lack of temporal association, at least in LCMV-WE infection, between the appearance of nAb and clearance, prompted us to study nonneutralizing antibody (non-nAb) responses. The glycoprotein (GP) is the only surface determinant on LCMV particles. It is synthesized as a precursor protein and is posttranslationally cleaved into GP1 and GP2 subunits that remain noncovalently associated [41]. GP1 makes up an outer globular domain, whereas GP2 forms a membrane-anchored stalk [41]. Hence, GP1 is accessible on the infectious virion surface, rendering this antibody specificity of particular interest. Here, we exploited recently developed ELISA techniques [42] for measuring LCMV-WE GP1-specific antibodies. By day 12 after infection, LCMV-WE evoked a GP1-specific IgG response in C57BL/6 mice and at lower titers also in V10YEN mice, but not in T11muMT mice, correlating with virus control (Figure 1E, B cell-deficient muMT mice shown as negative controls). Thus, the timing of the GP1-binding antibody response as well as the differential magnitude in C57BL/6, VI10YEN and T11muMT mice matched best the pattern of virus clearance.
###end p 15
###begin title 16
Viral Clearance or Persistence Depends on BCR Repertoire Diversity and Correlates with Antiviral Antibody Formation
###end title 16
###begin p 17
###xml 152 153 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 188 189 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 197 201 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
B cell-deficient (muMT in [A, C, and E]; JHT in [B and D]), BCR-restricted T11muMT and VI10YEN mice, and control C57BL/6 mice were infected i.v. with 106 PFU of LCMV-WE (A, C, and E) or 106 PFU of LCMV Clone 13 (B and D).
###end p 17
###begin p 18
###xml 355 356 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 415 416 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 447 448 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 365 369 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
(A and B) Infectious virus in blood was monitored over time. Numbers next to the VI10YEN curve in (A) indicate viremic VI10YEN mice per number of mice tested at each time point. Comparison of viral clearance kinetics (combined analysis of up to three experiments): LCMV-WE (A) C57BL/6 versus all other groups, VI10YEN versus T11muMT, VI10YEN versus muMT, p < 0.01. LCMV Clone 13 (B) C57BL/6 versus all other groups p < 0.05. All other comparisons p > 0.05.
###end p 18
###begin p 19
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C and D) nAbs were monitored over time. Double asterisks (**) indicate p < 0.01.
###end p 19
###begin p 20
###xml 143 144 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 188 189 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 4 8 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
(E) LCMV-WE-GP1-specific IgG was measured by ELISA. Symbols represent the mean +/- SEM of four mice per group. A single asterisk (*) indicates p < 0.05, and double asterisks (**) indicate p < 0.01.
###end p 20
###begin p 21
###xml 181 185 <span type="species:ncbi:10090">mice</span>
For (A and C), one representative experiment of three similar experiments is shown. (E) displays one of two experiments, with symbols representing the mean +/- SEM of three to five mice per group.
###end p 21
###begin title 22
Both Adaptive IgM and IgG Are Needed for Efficient Virus Control
###end title 22
###begin p 23
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b027">27</xref>
###xml 498 501 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b043">43</xref>
###xml 512 515 512 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 696 704 696 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 724 727 724 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 798 806 798 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 812 813 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 104 108 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 296 300 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 639 643 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
###xml 971 975 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
Next, we assessed the individual contribution of IgM and IgG responses to virus control. All monoclonal LCMV nAbs characterized today are of an IgG isotype, and so is the late nAb response observed in the course of natural infection [27]. Hence, any potential role of antibodies in resolution of LCMV infection had previously been accredited to IgG. To test for the role of class switch-dependent isotypes including IgG, we used gene-targeted mice lacking activation-induced cytidine deaminase (AID-/-) [43]. AID-/- mice are unable to undergo class-switch recombination and somatic hypermutation, and in our experiments, could not resolve LCMV-WE infection during the observation period of 96 d (Figure 2A). As expected, AID-/- mice displayed a complete absence of nAbs and GP1-specific serum IgG (Figure 2C and 2E), suggesting that immunoglobulin class-switch recombination and IgG production together with somatic hypermutation are essential steps in the resolution of LCMV infection.
###end p 23
###begin title 24
Virus Control Requires Secreted IgM and Also AID-Dependent Class-Switch Recombination and Affinity Maturation
###end title 24
###begin p 25
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 414 417 412 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 428 431 426 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 437 440 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 453 454 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 501 504 499 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 504 505 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 575 576 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 6 10 <span type="species:ncbi:10090">Mice</span>
###xml 68 72 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 156 160 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 463 467 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
(A-E) Mice of the indicated genotypes were infected with 106 PFU of LCMV-WE (A, C, and E) or Clone 13 (B and D) i.v. Viremia (A and B), nAbs (C and D), and LCMV-WE-GP1-binding antibodies (E) were monitored over time. Symbols represent the mean +/- SEM of three to four (A, C, and E) or nine to ten (B and D) mice per group. Comparison of viral clearance kinetics: LCMV-WE (A): C57BL/6 versus all other groups, sIgM-/- versus AID-/-, sIgM-/- versus JHT, p < 0.05. LCMV Clone 13 (B): C57BL/6 versus sIgM-/-p < 0.01, as indicated by double asterisks (**). All other comparisons p > 0.05. n.s., not significant.
###end p 25
###begin p 26
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b044">44</xref>
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 370 373 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 447 448 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 467 476 466 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sg003">Figure S3</xref>
###xml 571 574 570 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 617 625 616 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 775 778 774 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 937 945 936 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 883 887 <span type="species:ncbi:10090">mice</span>
To assess a potential role of IgM antibodies we exploited the sIgM-/- mouse model [44]. sIgM-/- B cells express IgM as their surface receptor and secrete IgG upon class-switch recombination but are unable to secrete the early IgM isotype. Experiments were carried out to confirm that according to expectations and unlike B cell-deficient muMT mice, B cell-competent sIgM-/- mice display a normal lymphoid microarchitecture and mount unimpaired CD4+ T cell responses (Figure S3). Surprisingly, however, LCMV-WE infection resulted in substantially prolonged viremia in sIgM-/- mice as compared to C57BL/6 control mice (Figure 2A), suggesting that contrary to expectations, an antibody response of IgM isotype contributed to virus control. More strikingly even, nine of ten sIgM-/- mice failed to resolve LCMV Clone 13 infection for a period of at least 100 d, whereas all nine C57BL/6 mice had cleared viremia within 42 d after infection (Figure 2B and unpublished data).
###end p 26
###begin p 27
###xml 59 67 59 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 73 74 73 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 170 173 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 344 347 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 406 409 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 529 537 529 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 676 679 676 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 788 791 788 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 857 858 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 885 893 885 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 998 1006 998 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 1009 1010 1009 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1157 1160 1157 1160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1168 1176 1168 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 1240 1248 1240 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 1385 1393 1385 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b045">45</xref>
###xml 1682 1690 1682 1690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 280 284 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
###xml 870 874 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 979 983 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1119 1123 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1162 1166 <span type="species:ncbi:10090">mice</span>
###xml 1227 1232 <span type="species:ncbi:10090">mouse</span>
###xml 1453 1457 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
The analysis of nAb responses (measuring both IgM and IgG, Figure 2C and 2D), confirmed that the kinetics and magnitude of the nAb response were indistinguishable in sIgM-/- and C57BL/6 controls, and therefore, likely were of IgG isotype as previously reported. As expected, also LCMV-WE-GP1-binding IgG responses showed normal kinetics in sIgM-/- mice. Somewhat higher GP1-specific IgG peak titers in sIgM-/- mice as compared to C57BL/6 control mice were likely the result of prolonged viremia with an increased antigen burden (Figure 2E). In support of this notion, differences in antibody titers became particularly apparent between day 12 and 20 when C57BL/6, but not sIgM-/-, mice had cleared the infection. The above experiments had suggested that differences in virus loads of sIgM-/- and C57BL/6 mice were manifest as early as 1 wk after infection (p < 0.01 for LCMV Clone 13, Figure 2B). Additional experiments corroborated this difference in early virus loads also for LCMV-WE infection (Figure 3A, p < 0.01). As a likely mediator of this difference, ELISA assays detected GP1-specific IgM responses in day 8 LCMV-WE-infected C57BL/6, but not sIgM-/-, mice (Figure 3B), antibodies that were absent from naive C57BL/6 mouse serum (Figure 3B). Importantly also, the GP1-specific IgM responses measured here were confirmed to be entirely antigen-specific since total serum IgM (Figure 3C), unlike serum IgG [45], remained largely unaltered after LCMV infection. A time-course analysis revealed that GP1-specific IgM was highest on day 4 and 7 after infection, followed by a continuous decline of this isotype concomitant with class switch and appearance of GP1-specific IgG (Figure 3D). These assays were, however, performed with unseparated serum, and competition between IgG and IgM in ELISA may have resulted in an underestimation of IgM levels at later time points.
###end p 27
###begin title 28
Early Adaptive IgM Response Rather Than Natural Antibodies Contributes to Virus Control
###end title 28
###begin p 29
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 69 73 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 95 99 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
(A-C) sIgM-/- and C57BL/6 control mice were infected with 106 PFU of LCMV-WE i.v. Viremia (A), LCMV-WE-GP1-specific IgM (B), and total serum IgM (C) were determined 8 d later. Bars represent the mean +/- SEM of five to ten mice per group.
###end p 29
###begin p 30
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 47 51 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 60 64 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
(D) C57BL/6 mice were infected with 106 PFU of LCMV-WE i.v. LCMV-WE-GP1-specific IgM and IgG were measured over time. Symbols represent the mean +/- SEM of four mice per group.
###end p 30
###begin p 31
###xml 14 17 14 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 121 124 121 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
(E and F) sIgM-/- mice were substituted i.p. with 2 ml of naive C57BL/6 serum on day -1. Control groups consisted of sIgM-/- and C57BL/6 mice without serum substitution. All mice were infected with 106 PFU of LCMV-WE i.v. on day 0. Total serum IgM was measured on the day of virus challenge (E), and viremia was determined on day 21 (F). Bars represent the mean +/- SEM of five to twelve animals.
###end p 31
###begin p 32
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
A single asterisk (*) indicates p < 0.05, and double asterisks (**) indicate p < 0.01. n.s., not significant.
###end p 32
###begin p 33
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b046">46</xref>
###xml 213 216 213 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 254 262 254 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 387 390 387 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 429 437 429 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 644 647 644 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 241 246 <span type="species:ncbi:10090">mouse</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 668 672 <span type="species:ncbi:10090">mice</span>
sIgM-/- mice not only lack adaptive IgM responses but also natural IgM, which contributes to control of other viral infections [46]. For dissecting the role of preexisting natural antibodies, we reconstituted sIgM-/- mice with naive C57BL/6 mouse serum (Figure 3E). Despite reaching total serum IgM levels at least equivalent to normal C57BL/6 mice, reconstitution of natural IgM in sIgM-/- mice failed to restore virus control (Figure 3F). Taken together, these data demonstrated that adaptive IgM as well as IgG responses both played essential roles in the efficient resolution of LCMV infection. Interestingly, unaltered nAb kinetics in sIgM-/- and C57BL/6 control mice suggested that antiviral IgM mediated its effects by mechanisms other than classical virus neutralization.
###end p 33
###begin title 34
###xml 82 86 <span type="species:ncbi:10090">Mice</span>
Antibody Therapy Prevents Viral Persistence and Preserves CTL Function in T11muMT Mice
###end title 34
###begin p 35
###xml 323 331 322 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 521 529 518 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g001">Figure 1</xref>
###xml 686 689 679 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 694 697 683 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 704 706 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b047">47</xref>
###xml 803 811 785 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 88 92 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
###xml 698 702 <span type="species:ncbi:10090">mice</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
###xml 909 913 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1042 1046 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
Next, we studied whether antibody therapy could restore virus control in BCR-restricted LCMV noncontroller mice. For this purpose, we infected T11muMT mice with LCMV-WE and treated them on day 4 and day 7 with either normal serum (negative control) or with normal serum reconstituted with GP1-specific monoclonal antibody (Figure 4A). T11muMT mice treated with GP1-specific antibody eliminated LCMV as efficiently as did C57BL/6 wild-type mice, whereas control-treated T11muMT mice remained viremic, as expected (compare Figure 1A). The same antibody treatment that was successful in T11muMT mice failed, however, to exert a detectable effect on virus loads when administered to TCRbeta-/-delta-/- mice [47] lacking T cells owing to homozygous deletion of the T cell receptor beta and delta chain loci (Figure 4B). These data were compatible with the interpretation that T cells of T11muMT mice could control LCMV infection if appropriately aided by specific antibodies, whereas neither T cells nor antibody therapy was sufficient to control LCMV on its own.
###end p 35
###begin title 36
###xml 82 86 <span type="species:ncbi:10090">Mice</span>
Antibody Therapy Prevents Viral Persistence and Preserves CTL Function in T11muMT Mice
###end title 36
###begin p 37
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 557 558 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 645 646 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 678 679 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 10 14 <span type="species:ncbi:10090">Mice</span>
###xml 72 76 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
(A and B) Mice of the indicated genotypes were infected with 106 PFU of LCMV WE. On day 4 and day 7 (arrows), they were treated with GP1-specific antibody in normal serum or with normal serum only (control), as outlined in the chart. Viremia was monitored over time. Symbols represent the mean +/- SEM of four to five mice per group. The data in (A and B) originate from the same experiment, and the identical C57BL/6 group is shown in both graphs. Virus clearance kinetics in C57BL/6 mice and anti-GP1 antibody-treated T11muMT mice were indistinguishable (p > 0.05), but each one of them differed significantly from the remaining three groups (p < 0.01). All other comparisons p > 0.05.
###end p 37
###begin p 38
###xml 158 159 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 364 365 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
(C-F) C57BL/6 and T11muMT mice were treated as in (A and B). On day 7 (C and D) and day 35 (E and F) after infection, virus-specific cytotoxic activity of CD8+ T cells was measured in an in vivo CTL assay (C and E), and virus loads were determined in blood (D and F). Bars represent the mean +/- SEM of three to five mice per group. Double asterisks (**) indicate p < 0.01. n.s., not significant.
###end p 38
###begin p 39
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b048">48</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b049">49</xref>
###xml 387 396 381 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sg001">Figure S1</xref>
###xml 514 522 508 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 622 630 616 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 827 835 820 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 912 920 904 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 253 257 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 879 883 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
###xml 1235 1239 <span type="species:ncbi:10090">mice</span>
Exhaustion of CD8 T cell responses as a result of continued antigen exposure is a common observation in persistent viral infection [48,49]. Hence, we investigated whether antibody therapy could prevent CD8 T cell exhaustion in T11muMT mice. The initial LCMV-specific CD8 T cell response of T11muMT mice not only was of normal frequency and was functional in terms of IFNgamma secretion (Figure S1D) but also displayed an unimpaired capacity for killing antigenic cells in vivo, irrespective of antibody treatment (Figure 4C). Of note, virus loads were still similar in all groups when these tests were performed on day 7 (Figure 4D). On the contrary, defective cytolytic activity was observed in control-treated T11muMT mice on day 35 during the chronic phase of infection. Prevention of viral persistence by antibody therapy (Figure 4F) restored in vivo cytotoxicity of T11muMT mice to normal levels on day 35 (Figure 4E). This lent further support to the interpretation that the CD8 T cell response of T11muMT mice was intrinsically normal, and that its decline during chronic infection was merely the result of viral persistence rather than the cause thereof. Albeit less likely, a subtle intrinsic CD8 T cell deficiency of T11muMT mice cannot, however, be formally excluded. Irrespective thereof, antibody therapy may help preserve the antiviral CD8 T cell response.
###end p 39
###begin title 40
Unimpaired Virus Clearance in the Absence of the Classical and Alternative Complement Cascades, of the Fc Receptor gamma Chain or of Fc gamma Receptor IIB
###end title 40
###begin p 41
###xml 215 218 215 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 220 223 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 234 255 234 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 333 341 333 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g005">Figure 5</xref>
###xml 559 562 547 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 564 566 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b050">50</xref>
###xml 578 581 562 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 770 778 753 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g005">Figure 5</xref>
###xml 1010 1013 969 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1019 1040 978 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1089 1097 1048 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g005">Figure 5</xref>
###xml 156 160 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 993 997 <span type="species:ncbi:10090">mice</span>
###xml 1047 1051 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 1362 1366 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
To evaluate the role of the classical and alternative complement cascades as major effector pathways of antibody-mediated immunity, we studied clearance of LCMV-WE in mice lacking complement components C3 and C4 (C3-/-C4-/- mice; see Materials and Methods). C3-/-C4-/- mice resolved viremia as efficiently as wild-type control mice (Figure 5A), whereas B cell-deficient JHT control mice remained viremic throughout. An analogous experiment was carried out in mice lacking Fc gamma receptors I, III, and IV owing to deletion of the common gamma chain (FcRgamma-/- [50]). FcRgamma-/- mice cleared LCMV-WE infection as efficiently as did C57BL/6 wild-type mice, whereas B cell-deficient JHT and T11muMT mice both showed unchecked viremia throughout the observation period (Figure 5B). Unlike Fc gamma receptors I, III, and IV, Fc gamma receptor IIB (FcgammaRIIB) expression does not depend on the common gamma chain. To study the contribution of this receptor, we infected FcgammaRIIB -deficient mice (FcgammaRIIB-/-; see Materials and Methods) with LCMV, but found unimpaired virus control (Figure 5C). Taken together, these data excluded an essential individual contribution of classical and alternative complement cascades, of Fc gamma receptors I, III, and IV, and of FcgammaRIIB, respectively, in mediating protective antibody effects in the natural course of LCMV infection.
###end p 41
###begin title 42
Efficient Virus Clearance Occurs in the Absence of Either Complement, Fc Receptor gamma Chain, or FcgammaRIIB
###end title 42
###begin p 43
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 219 222 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 224 227 222 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 292 300 290 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 303 304 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 383 391 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 463 466 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 468 471 466 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 471 472 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 521 524 519 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 526 529 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 541 542 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 579 582 573 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 603 604 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 683 686 671 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 711 714 694 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 727 728 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 767 770 746 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 770 771 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 62 66 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
Mice of the indicated genotypes were infected with 106 PFU of LCMV-WE, and viremia was monitored over time. Symbols represent the mean +/- SEM of three to four mice per group. (A-C) represent independent experiments. C3-/-C4-/- mice were tested alongside the experimental groups displayed in Figure 2A, 2B, and 2C, and hence the identical C57BL/6 and JHT control groups are shown in Figure 2A and (A). Comparison of viral clearance kinetics: (A) C57BL/6 versus C3-/-C4-/-p > 0.05 (not significant); C57BL/6 versus JHT, C3-/-C4-/- versus JHT p < 0.05. (B) C57BL/6 versus FcRgamma -/-, JHT versus T11muMT p > 0.05 (not significant); C57BL/6 versus JHT, C57BL/6 versus T11muMT, FcRgamma-/- versus T11muMT, FcRgamma-/- versus JHT, p < 0.05. (C) C57BL/6 versus FcgammaRIIB-/-p > 0.05 (not significant).
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b019">19</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b021">21</xref>
###xml 164 170 <span type="species:ncbi:10090">murine</span>
###xml 180 184 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 339 342 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 347 350 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The present data show that virus-specific antibody responses, including early IgM, play an unexpected key role in preventing viral chronicity in the CTL-controlled murine model of LCMV infection. These observations are compatible with the rapid escape from antibody recognition seen in other primarily CTL-controlled infections, including HIV and HCV [19-21], and indicate that specific antibody responses represent a level of antiviral pressure that tends to be underappreciated.
###end p 45
###begin p 46
###xml 207 215 207 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 323 332 323 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figures 2</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">3</xref>
###xml 536 544 536 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b051">51</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b042">42</xref>
###xml 127 131 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 241 245 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 259 263 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 471 475 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 861 865 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
The observed antiviral effects can only be partially accredited to antibody-mediated virus neutralization. Albeit clearance of LCMV Clone 13 in C57BL/6 mice did coincide with the appearance of nAbs (compare Figure 2B and 2D), IgM effects on LCMV Clone 13 and LCMV-WE titers were evident already on day 7/8 after infection (Figures 2A, 2B, and 3A) at a time when nAbs were undetectable even if using virtually undiluted serum for the assays (unpublished data). Similarly, LCMV-WE was cleared weeks before nAbs could be detected (compare Figure 2A and 2C). Obviously, "absence of proof" for early nAb does not equate "proof of absence," and we recognize that "nAb consumption" during viremia or subsequent phases of protracted clearance from tissues [51] would provide an explanation for our inability to detect nAbs. However, we favor the idea that the delay in LCMV nAb detection, relative to the antiviral effects observed, rather results from the need for time-intensive affinity maturation [42].
###end p 46
###begin p 47
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b052">52</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b053">53</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b054">54</xref>
###xml 1048 1050 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b055">55</xref>
###xml 1423 1425 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b050">50</xref>
###xml 1426 1428 1418 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b056">56</xref>
###xml 1431 1439 1423 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g005">Figure 5</xref>
###xml 1625 1627 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b057">57</xref>
###xml 1669 1678 1656 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figures 2</xref>
###xml 1681 1682 1668 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 1689 1690 1676 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">3</xref>
The protective capacity of nAbs is classically explained by "virion occupancy," i.e., sterical hindrance interfering with cell-surface receptor binding [52]. Non-nAbs, on the other hand, may mediate protection via a number of mechanisms, including: (1) virion occupancy by complement C1q binding to a virion-bound antibody [53], (2) complement cascade activation, leading to further virion occupancy through covalent opsonization, (3) complement-mediated virion lysis, (4) Fc-receptor-mediated virion phagocytosis and destruction, (5) Fc-receptor-mediated stimulation of the innate immune system, (6) immune complex formation and resulting modification of tissue distribution and cellular tropism, (7) antibody-dependent cellular cytotoxicity (ADCC), via antibody binding to viral surface proteins on infected cells, (8) impaired virus production, through antibody-mediated cross-linking of cell surface-expressed viral envelope protein [54], or (9) destruction of target protein or host cells, through antibody-mediated reactive oxygen catalysis [55]. Although a full assessment of the individual contribution of each of these potential pathways lies outside the scope and intention of the present study, we do present data ruling out a major individual contribution for covalent complement opsonization and lysis, mediated through C3 and/or C4 activation, as well as for FcRgamma- and FcgammaRIIB-facilitated mechanisms [50,56] (Figure 5). It remains possible that another mechanism not yet experimentally addressed here may account for most of the antibody effects observed, e.g., Fc alpha/mu receptor-mediated clearance [57] could explain the observed IgM effects (Figures 2A, 2B, and 3A). However, substantial redundancy in these multiple mechanisms may render it difficult to work out the contribution of individual mechanisms including the ones we have tested here, i.e., in the absence of a specific pathway, compensation by the remaining ones may suffice for virus clearance.
###end p 47
###begin p 48
###xml 248 251 244 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 256 259 248 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 269 277 261 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">Figure 4</xref>
###xml 283 284 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g004">4</xref>
###xml 606 614 598 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g003">Figure 3</xref>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
The present findings are of considerable importance for our understanding of virus-host relationship in persistent infection and for refining preventive and therapeutic strategies: The success of antibody therapy in T11muMT mice, but not in TCRbeta-/-delta-/- animals (Figure 4A and 4B), suggests a synergistic effect of cellular and humoral immune defense, at least for LCMV. Antibody therapy can apparently help preserve T cell function, and hence early administration may be most promising. Albeit our experimental therapy was administered during a phase of infection in which IgM predominates (compare Figure 3D), IgG was efficient. This may be of practical importance since both vaccination and immunotherapy typically rely on IgG rather than on IgM.
###end p 48
###begin p 49
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b020">20</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b058">58</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b059">59</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b060">60</xref>
###xml 205 209 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
Owing to structural reasons, potent nAb responses against persisting viruses are generally difficult to elicit through vaccination [20,58], but non-nAbs represent an attainable goal. The present data from LCMV infection in mice strongly suggest that non-nAbs, alongside antiviral CTL responses and nAbs, can determine clearance or persistence. We suggest that non-nAbs operate by blunting the infection and thereby strengthening the efficacy of other immune mediators such as CTLs and nAbs, but also NK cells [59,60]. In the context of the cited literature, our data support the idea that antibodies should be considered anew in vaccination strategies aimed at combating persistent viral disease, and that aside from nAbs as a vaccine goal, non-nAbs also should be induced and assessed.
###end p 49
###begin p 50
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b027">27</xref>
###xml 294 302 294 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 361 369 361 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">Figure 2</xref>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-1000080-g002">2</xref>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 54 58 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
It has recently been shown that non-nAbs specific for LCMV GP-1 can mediate protective effects when expressed in a transgenic context [27]. In nontransgenic wild-type mice, we now show that virus-specific antibody responses, including GP-1-binding IgM, are not only generated rapidly (see also Figure 2G), but also exert significant antiviral pressure (compare Figure 2B and 2F; p < 0.01) in the days before nAbs become detectable. Although we focused in our assays on GP-1 binding antibodies, it remains entirely possible that additional non-nAbs of alternative specificities may also contribute to the observed protective effects. Defining characteristics and specificities of "protective" and "nonprotective" non-nAbs may therefore represent an important next step in the direction of exploiting the protective capacity of non-nAbs for vaccination and immunotherapy.
###end p 50
###begin p 51
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b061">61</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b062">62</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b063">63</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b064">64</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b065">65</xref>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b066">66</xref>
###xml 1200 1202 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b067">67</xref>
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 295 298 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 386 389 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 520 523 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 714 717 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 854 857 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1187 1190 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Failure of the HIV AIDSVax trial eliciting mostly non-nAbs in the absence of cell-mediated immunity has somewhat dampened the hope that non-nAbs could help containing persistent infections [61,62]. Albeit non-nAbs are apparently unable to protect on their own, studies have correlated ADCC with HIV nonprogression, suggesting that non-nAbs may indeed contribute to long-term control of HIV [63]. However, much remains unclear about the overall importance of non-nAbs, and antibodies in general, to the natural course of HIV infection [64]. Moreover, the available data emphasize that the mechanisms of antibody-mediated protection do not always follow the traditional way of thinking. For instance, even a broadly HIV-neutralizing monoclonal antibody was shown to protect primarily via Fc-receptor-dependent mechanisms [65]. Of note in this context, the HIV envelope displays defective glycoproteins in great abundance [66]. Albeit unable to mediate cell entry, such defective glycoproteins are highly immunogenic and may represent efficient targets for non-nAbs. Of further importance here, non-nAbs have a relatively broad spectrum of activity against both autologous and heterologous HIV strains [67].
###end p 51
###begin p 52
Taken together, the results from this study show that CD8 T cells, even if firmly established as the predominant mechanism of antiviral immune defense, need support from specific antibodies to prevail and prevent viral persistence. Given the relative ease of induction of non-nAbs (relative to nAbs), combined with the observed protective effects, our findings may provide new impetus for inclusion of antibody targets in vaccines against persistent viral diseases.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and animal experiments.
###end title 54
###begin p 55
###xml 28 31 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 33 35 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b038">38</xref>
###xml 41 44 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 46 48 45 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b039">39</xref>
###xml 60 62 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b036">36</xref>
###xml 74 76 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b037">37</xref>
###xml 83 85 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b040">40</xref>
###xml 91 94 89 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 96 98 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b043">43</xref>
###xml 105 108 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 110 112 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b044">44</xref>
###xml 117 120 115 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 122 125 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 167 170 165 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 172 174 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b068">68</xref>
###xml 182 185 180 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 187 189 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b069">69</xref>
###xml 205 208 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 213 216 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 218 220 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b047">47</xref>
###xml 235 238 222 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 240 242 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b050">50</xref>
###xml 408 411 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 857 860 832 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 861 865 <span type="species:ncbi:10090">mice</span>
###xml 912 917 <span type="species:ncbi:10090">mouse</span>
C57BL/6 wild-type mice, muMT-/- [38], JHT-/- [39], T11muMT [36], VI10YEN [37], QM [40], AID-/- [43], sIgM-/- [44], C3-/-C4-/- double-deficient mice (a crossbreed of C3-/- [68] and C4-/- [69] mice), TCRbeta-/-delta-/- [47], and FcRgamma-/- [50] were bred at the Institute of Laboratory Animal Science, University of Zurich, and were housed under specific pathogen-free (SPF) conditions throughout. FcgammaRIIB-/- mice on a pure C57BL/6 background, in which exons 4 and 5, encoding the ligand-binding EC2 and transmembrane (TM) region, have been deleted by gene targeting in Bruce4 ES cells (C57BL/6 background), were generated in the laboratory of Sjef Verbeek. Absence of functional FcgammaRIIB was confirmed both in functional in vivo and in vitro assays and at the protein level, as will be described elsewhere in more detail. Experiments with FcgammaRIIB-/- mice and controls were performed in a conventional mouse facility. Animal experiments were carried out at the University of Geneva and the University of Zurich with authorization by the respective cantonal authorities and in accordance with the Swiss law for animal protection.
###end p 55
###begin title 56
Viruses, infection, and antibody therapy.
###end title 56
###begin p 57
###xml 317 318 317 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 383 386 379 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 391 394 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 440 442 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b070">70</xref>
###xml 0 4 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 132 136 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
LCMV-WE was originally obtained from F. Lehmann-Grube (Heinrich-Pette Institut, Hamburg, Germany) and was propagated on L929 cells. LCMV Clone 13 was obtained originally from R. Ahmed (Emory University, Atlanta, Georgia, United States) and was grown on BHK-21 cells. Infections were performed at a standard dose of 106 PFU by the intravenous route. For therapy of T11muMT and TCRbeta-/-delta-/- mice, GP1-specific monoclonal antibody KL25 [70] was administered intraperitoneally on day 4 (100 mug) and on day 7 (1 mg), reconstituted in 400 mul of normal (nonimmunized and uninfected) C57BL/6 serum. Control animals were given 400 mul of normal serum.
###end p 57
###begin title 58
###xml 33 37 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
Virus titration and detection of LCMV-neutralizing antibodies.
###end title 58
###begin p 59
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b071">71</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b058">58</xref>
###xml 0 4 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 115 119 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 127 131 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
LCMV virus stocks and blood samples were titrated by standard immunofocus assays on MC57G cells [71]. nAbs against LCMV-WE and LCMV Clone13 were measured in an immunofocus reduction assay using the respective homologous virus as described [58].
###end p 59
###begin title 60
Enzyme-linked immunosorbent assays (ELISA).
###end title 60
###begin p 61
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b042">42</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b042">42</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b045">45</xref>
###xml 220 224 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 259 264 <span type="species:ncbi:9606">human</span>
###xml 320 325 <span type="species:ncbi:10090">mouse</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
GP1-specific IgM and IgG responses were measured by ELISA using a GP1-Fc fusion construct produced in an eukaryotic system as described [42]. In the GP1-Fc construct, amino acids 1-265 (i.e., the GP1 domain [42]) of the LCMV-WE glycoprotein gene are fused to human Fc. As sole modification to the published method, anti-mouse IgM monoclonal antibody coupled to HRP (Sigma) was used instead of anti-mouse IgG when detecting GP1-specific IgM. Total serum IgM titers were measured in ELISA as described previously [45]. Titers displayed represent the serum dilution yielding twice background optical density values.
###end p 61
###begin title 62
Enumeration of epitope-specific T cell populations and in vivo CTL assay.
###end title 62
###begin p 63
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b072">72</xref>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 349 350 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Single-cell suspensions of splenocytes were used for intracellular cytokine assays as described [72]. Restimulation of virus-specific cells was performed for 5-6 h in the presence of the following synthetic peptides at 10-6 M concentration: KAVYNFATC (GP33, CD8+ T cells), GPDIYKGVYQFKSVEFD (GP64, CD4+ T cells), and SGEGWPYIACRTSVVGRAWE (NP309, CD4+ T cells).
###end p 63
###begin p 64
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-1000080-b073">73</xref>
###xml 272 276 272 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 284 287 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 307 311 307 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 353 355 353 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 573 577 573 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 586 589 586 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 725 729 725 729 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 753 756 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 782 786 782 786 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 804 807 804 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
Cytotoxic activity of CD8+ T cells was measured in an in vivo CTL assay as previously described [73]. In brief, syngeneic C57BL/6 splenocytes were labeled with the fluorescent dye carboxyfluorescein diacetate succinimidyl ester (CFSE) at two different concentrations (CFSEhigh or CFSElow). In addition, CFSEhigh cells were pulsed with GP33 peptide at 10-6 M concentration for recognition by antiviral CTLs. 3 x 107 cells of each population were cotransferred into virus-infected recipient mice and into naive C57BL/6 mice (control). Five hours later, the percentage of CFSEhigh and CFSElow donor cells in peripheral blood mononuclear cells was determined by flow cytometry. Specific killing was calculated as: 100 - ([(% CFSEhigh in test animal / % CFSElow in test animal) / (% CFSEhigh in naive / % CFSElow in naive)] x 100).
###end p 64
###begin title 65
Immunohistochemistry.
###end title 65
###begin p 66
###xml 87 90 <span type="species:ncbi:10116">rat</span>
###xml 121 127 <span type="species:ncbi:10090">murine</span>
###xml 235 239 <span type="species:ncbi:9925">goat</span>
###xml 245 248 <span type="species:ncbi:10116">rat</span>
###xml 316 322 <span type="species:ncbi:9793">donkey</span>
###xml 328 332 <span type="species:ncbi:9925">goat</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 611 614 <span type="species:ncbi:10116">rat</span>
###xml 650 653 <span type="species:ncbi:10116">rat</span>
###xml 791 795 <span type="species:ncbi:9925">goat</span>
###xml 801 804 <span type="species:ncbi:10116">rat</span>
Histological analyses were performed on snap-frozen tissue. Sections were stained with rat monoclonal antibodies against murine B220 (Pharmingen), F4/80, MOMA1, and ERTR9 (all from BMA Biomedicals). Bound antibody was detected using a goat anti-rat antibody (Caltag Laboratories) and an alkaline phosphatase-coupled donkey anti-goat antibody (Jackson ImmunoResearch Laboratories) with naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic acid 2-methoxy anilide) phosphate and new fuchsin as a substrate. The sections were counterstained with hemalum. For tissues of VI10YEN mice carrying a light-chain transgene with rat constant domains, reaction of anti-rat monoclonal antibody with the transgenic light chain was prevented by using an alkaline phosphatase conjugated Fc gamma fragment-specific goat anti-rat IgG antibody as a secondary antibody (Jackson ImmunoResearch Laboratories).
###end p 66
###begin title 67
Statistical analysis.
###end title 67
###begin p 68
###xml 344 346 344 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t-</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 665 666 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
One-way analysis of variance (ANOVA) with the Least Significant Difference (LSD) post test was used for the comparison of individual values from multiple groups. Two-way ANOVA was performed to compare antibody responses over time. ANOVA was performed with SPSS version 13.0. Differences in individual values between two groups were analyzed by t-tests (unpaired, two-tailed), and virus clearance kinetics were compared in log-rank tests using GraphPad Prism software vs. 4.0b. Viral titers were log-transformed for statistical analysis, and viral clearance kinetics were compared in a Kaplan-Meier format. p-Values < 0.05 were considered statistically significant; p-values < 0.01 were considered highly significant.
###end p 68
###begin title 69
Supporting Information
###end title 69
###begin title 70
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 106 <span type="species:ncbi:10090">Mice</span>
Normal Splenic Microarchitecture and Unimpaired CD4+ and CD8+ T Cell Responses in T11muMT and VI10YEN Mice
###end title 70
###begin p 71
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
(A) Histological spleen sections of muMT, VI10YEN, T11muMT, and C57BL/6 control mice were stained for B220 (B cells), F4/80 (red pulp macrophages), ERTR9 (marginal zone macrophages), or MOMA-1 (metallophilic marginal zone macrophages) as indicated. Each image displays a representative area of spleen from three age-matched mice per group analyzed. Magnification bars indicate 200 mum.
###end p 71
###begin p 72
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 5 9 <span type="species:ncbi:10090">Mice</span>
###xml 67 71 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
(B): Mice of the indicated genotypes were infected with 106 PFU of LCMV-WE i.v. Eight days later, epitope-specific CD4+ (GP64 and NP309) and CD8+ (GP33) T cell frequencies in spleen were determined in an intracellular cytokine assay. Bars represent the mean +/- the standard error of the mean (SEM) of three (GP64, NP309) or three to eight animals (GP33) per group.
###end p 72
###begin p 73
(4.6 MB TIF)
###end p 73
###begin p 74
Click here for additional data file.
###end p 74
###begin title 75
###xml 48 52 <span type="species:ncbi:10090">Mice</span>
Delayed Virus Clearance in Quasimonoclonal (QM) Mice
###end title 75
###begin p 76
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 388 389 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 62 66 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
Mice of the indicated genotypes were infected with 106 PFU of LCMV-WE. Viremia (A) and nAbs (B) were monitored over time. Symbols represent the mean +/- SEM of two to five mice per group. One representative experiment of two similar ones is shown. Comparison of viral clearance kinetics (combined analysis of two experiments): QM versus C57BL/6, QM versus T11muMT, C57BL/6 versus T11muMT p < 0.01.
###end p 76
###begin p 77
(453 KB EPS)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin title 79
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 90 94 <span type="species:ncbi:10090">Mice</span>
Normal Splenic Microarchitecture and Unimpaired CD4+ and CD8+ T Cell Responses in sIgM-/- Mice
###end title 79
###begin p 80
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 286 295 285 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-1000080-sg001">Figure S1</xref>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
(A) Histological spleen sections of sIgM-/- were stained for B220 (B cells), F4/80 (red pulp macrophages), ERTR9 (marginal zone macrophages), or MOMA-1 (metallophilic marginal zone macrophages) as indicated. Sections of muMT and C57BL/6 mice are shown for comparison (same panels as in Figure S1A). Each image displays a representative area of spleen from three age-matched mice per group analyzed. Magnification bars indicate 200 mum.
###end p 80
###begin p 81
###xml 8 11 8 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 67 71 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
(B) sIgM-/- and C57BL/6 control mice were infected with 106 PFU of LCMV-WE i.v. Eight days later, epitope-specific CD4+ (GP64 and NP309) and CD8+ (GP33) T cell frequencies were determined in an intracellular cytokine assay. Bars represent the mean +/- SEM of three mice per group.
###end p 81
###begin p 82
(5.9 MB TIF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin title 84
###xml 73 77 <span type="species:ncbi:10090">Mice</span>
Normal Splenic Microarchitecture and Unimpaired CD4+ T Cell Responses in Mice with Restricted B Cell Receptor Diversity
###end title 84
###begin p 85
(65 KB DOC)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
We wish to thank Hans Hengartner and Rolf M. Zinkernagel for critical comments, suggestions, and long-term support, and Paul-Henri Lambert as well as Shozo Izui for important discussions.
###end p 87
###begin title 88
Abbreviations
###end title 88
###begin p 89
activation-induced cytidine deaminase
###end p 89
###begin p 90
B cell receptor
###end p 90
###begin p 91
cytotoxic T lymphocyte
###end p 91
###begin p 92
glycoprotein
###end p 92
###begin p 93
###xml 0 17 <span type="species:ncbi:11103">hepatitis C virus</span>
hepatitis C virus
###end p 93
###begin p 94
###xml 0 28 <span type="species:ncbi:12721">human immunodeficiency virus</span>
human immunodeficiency virus
###end p 94
###begin p 95
immunoglobulin M
###end p 95
###begin p 96
###xml 0 34 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
lymphocytic choriomeningitis virus
###end p 96
###begin p 97
neutralizing antibody
###end p 97
###begin p 98
nonneutralizing antibody
###end p 98
###begin p 99
plaque-forming unit
###end p 99
###begin p 100
quasimonoclonal
###end p 100
###begin title 101
References
###end title 101
###begin article-title 102
###xml 0 34 <span type="species:ncbi:11623">Lymphocytic choriomeningitis virus</span>
Lymphocytic choriomeningitis virus
###end article-title 102
###begin article-title 103
###xml 0 34 <span type="species:ncbi:11623">Lymphocytic choriomeningitis virus</span>
Lymphocytic choriomeningitis virus and immunology
###end article-title 103
###begin article-title 104
###xml 63 97 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response
###end article-title 104
###begin article-title 105
Functional analysis of T lymphocyte subsets in antiviral host defense
###end article-title 105
###begin article-title 106
###xml 24 58 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Immune response against lymphocytic choriomeningitis virus infection in mice without CD8 expression
###end article-title 106
###begin article-title 107
###xml 97 132 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
###end article-title 107
###begin article-title 108
###xml 98 133 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
###end article-title 108
###begin article-title 109
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
###end article-title 109
###begin article-title 110
###xml 65 94 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
###end article-title 110
###begin article-title 111
###xml 22 51 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
###end article-title 111
###begin article-title 112
###xml 106 134 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 164 179 <span type="species:ncbi:9544">rhesus macaques</span>
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric,m mkjl simian/human immunodeficiency virus during primary infections of rhesus macaques
###end article-title 112
###begin article-title 113
###xml 77 94 <span type="species:ncbi:10407">hepatitis B virus</span>
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection
###end article-title 113
###begin article-title 114
###xml 64 81 <span type="species:ncbi:11103">hepatitis C virus</span>
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection
###end article-title 114
###begin article-title 115
###xml 44 51 <span type="species:ncbi:9606">persons</span>
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy
###end article-title 115
###begin article-title 116
###xml 73 76 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HLA class I-restricted T cell responses may contribute to the control of HIV infection, but such responses are not always necessary for long-term virus control
###end article-title 116
###begin article-title 117
Toward an AIDS vaccine
###end article-title 117
###begin article-title 118
Viral persistence in vivo through selection of neutralizing antibody-escape variants
###end article-title 118
###begin article-title 119
Public versus personal serotypes of a viral quasispecies
###end article-title 119
###begin article-title 120
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
###end article-title 120
###begin article-title 121
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antibody neutralization and escape by HIV-1
###end article-title 121
###begin article-title 122
###xml 32 49 <span type="species:ncbi:11103">hepatitis C virus</span>
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
###end article-title 122
###begin article-title 123
Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts
###end article-title 123
###begin article-title 124
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 98 101 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
###end article-title 124
###begin article-title 125
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 121 126 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
###end article-title 125
###begin article-title 126
###xml 44 78 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 121 136 <span type="species:ncbi:10090">transgenic mice</span>
Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice
###end article-title 126
###begin article-title 127
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
###end article-title 127
###begin article-title 128
###xml 66 100 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread
###end article-title 128
###begin article-title 129
###xml 48 65 <span type="species:ncbi:11103">hepatitis C virus</span>
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge
###end article-title 129
###begin article-title 130
Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key
###end article-title 130
###begin article-title 131
###xml 57 91 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice
###end article-title 131
###begin article-title 132
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 141 175 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers
###end article-title 132
###begin article-title 133
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice
###end article-title 133
###begin article-title 134
###xml 66 93 <span type="species:ncbi:10310">herpes simplex virus type 2</span>
Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells
###end article-title 134
###begin article-title 135
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Deficient CD4+ T cell priming and regression of CD8+ T cell functionality in virus-infected mice lacking a normal B cell compartment
###end article-title 135
###begin article-title 136
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
###end article-title 136
###begin article-title 137
A crucial role for B cells in neuroinvasive scrapie
###end article-title 137
###begin article-title 138
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies
###end article-title 138
###begin article-title 139
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene
###end article-title 139
###begin article-title 140
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus
###end article-title 140
###begin article-title 141
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
A quasi-monoclonal mouse
###end article-title 141
###begin article-title 142
Arenaviridae: the viruses and their replication
###end article-title 142
###begin article-title 143
###xml 94 128 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus
###end article-title 143
###begin article-title 144
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme
###end article-title 144
###begin article-title 145
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM
###end article-title 145
###begin article-title 146
Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections
###end article-title 146
###begin article-title 147
Control of early viral and bacterial distribution and disease by natural antibodies
###end article-title 147
###begin article-title 148
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Peripheral lymphoid development and function in TCR mutant mice
###end article-title 148
###begin article-title 149
CD8 T cell dysfunction during chronic viral infection
###end article-title 149
###begin article-title 150
Viral immune evasion due to persistence of activated T cells without effector function
###end article-title 150
###begin article-title 151
FcR gamma chain deletion results in pleiotrophic effector cell defects
###end article-title 151
###begin article-title 152
Extralymphatic virus sanctuaries as a consequence of potent T-cell activation
###end article-title 152
###begin article-title 153
The antiviral activity of antibodies in vitro and in vivo
###end article-title 153
###begin article-title 154
Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components
###end article-title 154
###begin article-title 155
###xml 58 71 <span type="species:ncbi:11234">measles virus</span>
Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell
###end article-title 155
###begin article-title 156
Antibodies have the intrinsic capacity to destroy antigens
###end article-title 156
###begin article-title 157
Accelerated antigen presentation and elicitation of humoral response in vivo by FcgammaRIIB- and FcgammaRI/III-mediated immune complex uptake
###end article-title 157
###begin article-title 158
Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes
###end article-title 158
###begin article-title 159
Kinetics of protective antibodies are determined by the viral surface antigen
###end article-title 159
###begin article-title 160
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
KIR/HLA pleiotropism: protection against both HIV and opportunistic infections
###end article-title 160
###begin article-title 161
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS
###end article-title 161
###begin article-title 162
AIDS vaccines: back to 'plan A'
###end article-title 162
###begin article-title 163
AIDSVAX flop leaves vaccine field unscathed
###end article-title 163
###begin article-title 164
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression
###end article-title 164
###begin article-title 165
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Humoral immunity to HIV-1: neutralization and beyond
###end article-title 165
###begin article-title 166
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Fc receptor but not complement binding is important in antibody protection against HIV
###end article-title 166
###begin article-title 167
###xml 60 95 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
###end article-title 167
###begin article-title 168
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
###end article-title 168
###begin article-title 169
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity
###end article-title 169
###begin article-title 170
Regulation of the B cell response to T-dependent antigens by classical pathway complement
###end article-title 170
###begin article-title 171
###xml 0 34 <span type="species:ncbi:11623">Lymphocytic choriomeningitis virus</span>
Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization
###end article-title 171
###begin article-title 172
###xml 18 52 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates
###end article-title 172
###begin article-title 173
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA
###end article-title 173
###begin article-title 174
Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo
###end article-title 174
###begin p 175
currencya Current address: Institute for Systems Biology, Seattle, Washington, United States of America
###end p 175
###begin p 176
currencyb Current address: Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America
###end p 176
###begin p 177
currencyc Current address: Institute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany
###end p 177
###begin p 178
currencyd Current address: German Rheumatism Research Center Berlin, Berlin, Germany
###end p 178
###begin p 179
currencye Current address: Pharmacenter, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
###end p 179
###begin p 180
currencyf Current address: Novartis Institute for Tropical Diseases, Singapore, Singapore
###end p 180
###begin p 181
currencyg Current address: Intercell AG, Vienna, Austria
###end p 181
###begin p 182
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. AB, AV, ANH, MH, KF, C-AS, and DDP conceived and designed the experiments. AB, LF, AV, ANH, MH, KF, RS, EH, MF, AF, and DDP performed the experiments. AB, LF, AV, ANH, MH, KF, DM, RS, BO, C-AS, and DDP analyzed the data. BE, BMS, and JSV contributed reagents/materials/analysis tools. AB, AV, and DDP wrote the paper.
###end p 182
###begin p 183
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. AB was supported by a PhD scholarship of the Boehringer Ingelheim Fonds and by a postdoctoral fellowship of the Roche Research Foundation. ANH is a fellow of GRAKO1121 of the German Research Foundation. DDP holds a stipendiary professorship of the Swiss National Science Foundation (No. PP00A-114913) and was supported by grant No. 3100A0-104067/1 of the Swiss National Science Foundation.
###end p 183
###begin p 184
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 184

